retatrutide phase 2 nejm weight loss 48 weeks Early trial data for demonstrates exceptional results, reaching approximately 21% placebo-adjusted weight loss by week 48. This performance significantly exceeds all other leading obesity medications currently under Retatrutide produces up to 30.3%

quality with timely data and insights for employers, health plans and benefit consultants.

Growing evidence suggests that GLP-1 receptor agonists like semaglutide may offer unexpected benefits beyond weight loss, including potential migraine relief through metabolic and inflammatory pathways

This review article discusses the potential antidepressant effects of GLP-1RAs, especially in the context of their action on the processes related to neuroprotection, inflammation, stress response, energy metabolism, gut-brain crosstalk and the stability of the gut microbiota

Strive Compounding Pharmacy alleges the two pharma companies are coordinating an effort to restrict compounded access.

Emerging clinical trials and extensive preclinical research confirm Retatrutide's substantial efficacy in weight management